Clinical trials: Second-Line
Primary Immune Thrombocytopenia (ITP)
rhTPO Dose Escalation vs Eltrombopag Switch in ITP
This study is a prospective, multicenter, randomized controlled study, planning to enroll 110 ITP patients who failed to respond to conventional-dose rhTPO (300 IU/kg/d) after 14 days of treatment (PLT < 30×10⁹/L).
- Trial name
- NCT07476846
- Testing
- Recombinant Human Thrombopoietin（rhTPO）, Eltrombopag PfOS
- Volunteers
- 112 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
MSS Metastatic Colorectal Cancer
Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
The goal of this clinical trial is to learn about Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the treatment of second-line and above failure MSS(microsatellite stability) metastatic colorectal…
- Trial name
- NCT06613113
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05063552
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 172 sites in United States
- Volunteers
- 430 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
OPTIMOX1 in Chinese mCRC Patients
Previous OPTIMOX1 study investigated the use of oxaliplatin discontinuation and reintroduction in a novel stop-and-go strategy. Previously untreated patients were randomly assigned to either FOLFOX4 administered every 2 weeks…
- Trial name
- NCT01023633
- Testing
- Oxaliplatin, LV, 5-FU
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Nanjing Medical University
NSCLC
Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)
The last ASCO recommendations in 2003 for the treatment of a CBNPC of stage IIIB/IV of elderly people, are to manage a monochemotherapy.
- Trial name
- NCT00298415
- Testing
- Paclitaxel + Carboplatin, Monotherapy (gemcitabine or vinorelbine)
- Where
- 5 sites in France
- Volunteers
- 451 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Advanced Biliary Tract Adenocarcinoma
Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma
The purpose of this study is to determine whether sunitinib as second-line treatment in advanced biliary tract carcinoma
- Trial name
- NCT01082809
- Testing
- Sunitinib
- Where
- South Korea
- Volunteers
- 59 people
- Sponsor
- Samsung Medical Center
Esophageal Squamous Cell Cancer
Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT01993784
- Testing
- nimotuzumab
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking University
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
RATIONALE: Heat shock protein (HSP)90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01227018
- Testing
- STA-9090, Radiologic imaging, blood draw
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Non-small Cell Lung Cancer
Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
evaluate Erlotinib efficacy and safety as the 2nd/3rd line treatment in advanced or recurrent NSCLC with EGFR wild type and without c-met expression
- Trial name
- NCT02006043
- Testing
- Erlotinib 150mg
- Where
- 2 sites in China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Li Zhang
Non-Small Cell Lung Cancer
The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer
The development of anti-angiogenesis drugs has led to renewed enthusiasm in lung cancer treatments. Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor which selectively inhibits the vascular endothelial growth factor…
- Trial name
- NCT02515435
- Testing
- apatinib single agent
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tongji University
Breast Cancer
SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases
The aim of this project is to evaluate whether the sequence of Trastuzumab，pyrotinib and Nab-Paclitaxel in first line followed by SHR-A1811 in second line is superior to the sequence of SHR-A1811 in first line followed by…
- Trial name
- NCT06975475
- Testing
- SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Biliary Tract Neoplasms Immunotherapy
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
An investigation into the survival outcomes, progression-free survival, and safety of triple therapy with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib in patients with advanced HER2-positive/low-expressing biliary tract…
- Trial name
- NCT07704177
- Testing
- Trastuzumab Rezetecan, Adebrelimab, Lenvatinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Small Cell Lung Cancer
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
This study is an open, single-arm, single-center phase II clinical study, which aims to evaluate the efficacy and safety of adebelizumab combined with irinotecan liposome in the second-line treatment of advanced small cell lung…
- Trial name
- NCT07004712
- Testing
- Adebelizumab combined with irinotecan liposome as second-line therapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University Cancer Hospital & Institute
Prostate Cancer, CDK12 Gene Mutation
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
The aim of this study is to evaluate the efficacy and safety of vediximab monotherapy or in combination with enrolizumab for second-line treatment of CDK12 alterations mCRPC that has failed standard therapy.
- Trial name
- NCT06663007
- Testing
- RC48, Envafolimab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Tianjin Medical University Second Hospital
Adenocarcinoma, Non-Small-Cell Lung Carcinoma
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
The purpose of this study is to determine the effect of MGd in non-small-cell lung cancer (NSCLC) when given alone, and to evaluate the difference between two dosing regimens.
- Conditions
- Adenocarcinoma, Non-Small-Cell Lung Carcinoma, Lung Neoplasms
- Trial name
- NCT00129844
- Testing
- Motexafin Gadolinium
- Where
- 16 sites in United States, Canada
- Volunteers
- 108 people
- Sponsor
- Pharmacyclics LLC.
Advanced Gastric Cancer
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
This study will assess the safety and efficacy of AUY922, when administered, in combination with trastuzumab in adult patients with HER2+ advanced gastric cancer, who have received trastuzumab plus chemotherapy in the first line.
- Trial name
- NCT01402401
- Testing
- AUY922, Trastuzumab
- Where
- 15 sites in United States, Belgium and 6 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Epithelial Cancer Recurrent
A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer
A phase II single arm study of carboplatin and docetaxel in treatment of first sensitive relapse of epithelial ovarian, peritoneal or tubal cancer.
- Trial name
- NCT02026921
- Testing
- Carboplatin, Docetaxel
- Where
- 4 sites in Denmark, Finland and 1 more
- Volunteers
- 74 people
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Kidney Neoplasms
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
- Trial name
- NCT00678392
- Testing
- Axitinib (AG-013736), Sorafenib
- Where
- 294 sites in United States, Australia and 20 more
- Volunteers
- 723 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients
The myeloid-derived suppressor cells (MDSCs) can further trigger cytotoxic T cell apoptosis, and may shift the macrophages toward M2 subtype, inhibit the Th1 cell, and initiate other immune suppressive mechanism.
- Trial name
- QSYQT (NCT01802021)
- Testing
- Astagalus-based Formula: Qingshu-Yiqi-Tang
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Chang Gung Memorial Hospital
GastroEsophageal Cancer
Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer
Combining Erb inhibitors, such lapatinib, and TS inhibitors, such as capecitabine, may be a beneficial contribution to current treatment paradigms since preclinical data suggest that lapatinib alone can decrease TS mRNA and is…
- Trial name
- GastroLap (NCT01145404)
- Testing
- Lapatinib, Lapatinib plus capecitabine
- Where
- 16 sites in Germany
- Volunteers
- 76 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.